Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer

Liu,Xia; Zou,Jing; Su,Jie; Lu,Yi; Zhang,Jian; Li,Li; Yin,Fuqiang

doi:10.3892/ijo.2015.3254

Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer

Authors:
- Xia Liu
- Jing Zou
- Jie Su
- Yi Lu
- Jian Zhang
- Li Li
- Fuqiang Yin
View Affiliations

Affiliations: Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, Guangxi 530021, P.R. China
Published online on: November 19, 2015 https://doi.org/10.3892/ijo.2015.3254
Pages: 243-252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transient receptor potential cation channel, subfamily C, member 1 (TRPC1) participates in many physiological functions but has also been implicated in cancer development. However, little is known about the role of TRPC1 in ovarian cancer (OC), including the drug resistance of these tumors. In the present study, a significant and consistent downregulation of TRPC1 in drug-resistant OC tissues/cells was determined using real-time quantitative polymerase chain reaction assays and the microarrays deposited in Oncomine and Gene Expression Omnibus (GEO) profiles. Protein/gene-protein/gene and protein-chemical interactions indicated that TRPC1 interacts with 14 proteins/genes and 6 chemicals, all of which are involved in the regulation of drug resistance in OC. Biological process annotation of TRPC1, OC, and drug resistance indicated a role for TRPC1 in drug-resistance-related functions in OC, mainly via the cell cycle, gene expression and cell growth and cell death. Analysis of mRNA-microRNA interactions showed that 8 out of 11 major pathways enriched from 38 predominant microRNAs targeting TRPC1 were involved in the regulation of drug resistance in OC, and 8 out of these top 10 microRNAs were implicated in the drug resistance in ovarian and other cancers. In a clinical analysis using data obtained from The Cancer Genome Atlas project (TCGA) cohort on 341 OC patients, TRPC1 expression was found to differ significantly between grade 2 and grade 3 tumors, with low-level expression correlating with higher tumor grade. This is the first report to show a potential association between the downregulation of TRPC1 and both drug resistance and high histological tumor grade in OC. Our results provide the basis for further investigations of the drug-resistance-related functions of TRPC1 in OC and other forms of cancer.

View Figures

View References

1	Matsuo K, Eno ML, Im DD, Rosenshein NB and Sood AK: Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 116:61–65. 2010. View Article : Google Scholar
2	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
3	Agarwal R and Kaye SB: Ovarian cancer: Strategies for over-coming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
4	Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, et al: microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 5:29772014. View Article : Google Scholar : PubMed/NCBI
5	Shah JS, Cole AJ, Dickson KA, Soon P and Marsh DJ: Investigating the role of long non-coding RNAs in cisplatin resistance in ovarian cancer. Asia Pac J Clin Oncol. 10:42. 2014.
6	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
7	Suh DH, Kim MK, No JH, Chung HH and Song YS: Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann NY Acad Sci. 1229:53–60. 2011. View Article : Google Scholar : PubMed/NCBI
8	Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Tumor suppressor genes associated with drug resistance in ovarian cancer (Review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
9	Richardson A and Kaye SB: Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin F: Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar
11	Kahl CR and Means AR: Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev. 24:719–736. 2003. View Article : Google Scholar : PubMed/NCBI
12	Roderick HL and Cook SJ: Ca²⁺ signalling checkpoints in cancer: Remodelling Ca²⁺ for cancer cell proliferation and survival. Nat Rev Cancer. 8:361–375. 2008. View Article : Google Scholar : PubMed/NCBI
13	Rajewskaya TA, Goncharova SA, Konovalova NP, Kotelnikova RA and Tatyanenko LV: Effect of drug resistance modulator, NO donor, on membrane structure and function of membrane-bound Ca²⁺-activated Mg²⁺-dependent ATPase. Bull Exp Biol Med. 146:200–202. 2008. View Article : Google Scholar
14	Clapham DE, Runnels LW and Strübing C: The TRP ion channel family. Nat Rev Neurosci. 2:387–396. 2001. View Article : Google Scholar : PubMed/NCBI
15	Nilius B and Szallasi A: Transient receptor potential channels as drug targets: From the science of basic research to the art of medicine. Pharmacol Rev. 66:676–814. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ong HL and Ambudkar IS: The dynamic complexity of the TRPC1 channelosome. Channels (Austin). 5:424–431. 2011. View Article : Google Scholar
17	Selli C, Erac Y and Tosun M: Simultaneous measurement of cytosolic and mitochondrial calcium levels: Observations in TRPC1-silenced hepatocellular carcinoma cells. J Pharmacol Toxicol Methods. 72:29–34. 2015. View Article : Google Scholar
18	He B, Liu F, Ruan J, Li A, Chen J, Li R, Shen J, Zheng D and Luo R: Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells. Oncol Rep. 27:1548–1554. 2012.PubMed/NCBI
19	Tajeddine N and Gailly P: TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling. J Biol Chem. 287:16146–16157. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zeng B, Yuan C, Yang X, Atkin SL and Xu SZ: TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets. 13:103–116. 2013. View Article : Google Scholar
21	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
22	Edgar R, Domrachev M and Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar :
23	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multi-dimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
24	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
25	Zuberi K, Franz M, Rodriguez H, Montojo J, Lopes CT, Bader GD and Morris Q: GeneMANIA prediction server 2013 update. Nucleic Acids Res. 41(W1): W115–W122. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kuhn M, von Mering C, Campillos M, Jensen LJ and Bork P: STITCH: Interaction networks of chemicals and proteins. Nucleic Acids Res. 36(Database): D684–D688. 2008. View Article : Google Scholar :
27	Kuhn M, Szklarczyk D, Pletscher-Frankild S, Blicher TH, von Mering C, Jensen LJ and Bork P: STITCH 4: Integration of protein-chemical interactions with user data. Nucleic Acids Res. 42(D1): D401–D407. 2014. View Article : Google Scholar
28	de Leeuw N, Dijkhuizen T, Hehir-Kwa JY, Carter NP, Feuk L, Firth HV, Kuhn RM, Ledbetter DH, Martin CL, van Ravenswaaij-Arts CM, et al: Diagnostic interpretation of array data using public databases and internet sources. Hum Mutat. 33:930–940. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dweep H, Sticht C, Pandey P and Gretz N: miRWalk-database: Prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847. 2011. View Article : Google Scholar : PubMed/NCBI
30	Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v.20: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40(W1): W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et al; Australian Ovarian Cancer Study Group. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst. 106:1062014. View Article : Google Scholar
32	Meng D, Chen Y, Zhao Y, Wang J, Yun D, Yang S, Chen J, Chen H and Lu D: Expression and prognostic significance of TCTN1 in human glioblastoma. J Transl Med. 12:2882014. View Article : Google Scholar : PubMed/NCBI
33	Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
34	Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
35	Peters D, Freund J and Ochs RL: Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther. 4:1605–1616. 2005. View Article : Google Scholar : PubMed/NCBI
36	Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
37	Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 271:260–271. 2008. View Article : Google Scholar : PubMed/NCBI
38	Yan X, Fraser M, Qiu Q and Tsang BK: Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 102:348–355. 2006. View Article : Google Scholar : PubMed/NCBI
39	Wu H, Wang K, Liu W and Hao Q: PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Biochem Biophys Res Commun. 444:141–146. 2014. View Article : Google Scholar : PubMed/NCBI
40	Zhang X, Wang X, Song X, Liu C, Shi Y, Wang Y, Afonja O, Ma C, Chen YH and Zhang L: Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci. 101:2163–2170. 2010. View Article : Google Scholar : PubMed/NCBI
41	Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. Int J Oncol. 42:1305–1316. 2013.PubMed/NCBI
42	Sen T, Sen N, Noordhuis MG, Ravi R, Wu TC, Ha PK, Sidransky D and Hoque MO: OGDHL is a modifier of AKT-dependent signaling and NF-κB function. PLoS One. 7:e487702012. View Article : Google Scholar
43	Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li K, Fang Y, Weng D, Weng Y, et al: Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer. 11:3992011. View Article : Google Scholar : PubMed/NCBI
44	Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M and Lage H: Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 17:505–516. 2007.PubMed/NCBI
45	Moorehead RA and Singh G: Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol. 59:337–345. 2000. View Article : Google Scholar : PubMed/NCBI
46	Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer. 99:1269–1275. 2008. View Article : Google Scholar : PubMed/NCBI
47	Liu YY, Li L, Li DR, Zhang W and Wang Q: Suppression of WWOX gene by RNA interference reverses platinum resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi. 43:854–858. 2008.In Chinese. PubMed/NCBI
48	Liu T, Zhao L, Chen W, Li Z, Hou H, Ding L and Li X: Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway. Int J Mol Med. 33:1236–1242. 2014.PubMed/NCBI
49	Hamada H, Hagiwara K, Nakajima T and Tsuruo T: Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 47:2860–2865. 1987.PubMed/NCBI
50	Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL, Ren F and Li GF: Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One. 8:e710712013. View Article : Google Scholar
51	Lee LF, Haskill JS, Mukaida N, Matsushima K and Ting JP: Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol. 17:5097–5105. 1997. View Article : Google Scholar : PubMed/NCBI
52	Duan Z, Feller AJ, Penson RT, Chabner BA and Seiden MV: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 5:3445–3453. 1999.PubMed/NCBI
53	Huang Y, Ju B, Tian J, Liu F, Yu H, Xiao H, Liu X, Liu W, Yao Z and Hao Q: Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening. Oncol Rep. 31:1235–1248. 2014.PubMed/NCBI
54	Engelmann BJ, Ryan JJ and Farrell NP: Antidepressants and platinum drugs. Anticancer Res. 34:509–516. 2014.PubMed/NCBI
55	Lee CS, Kim YJ, Jang ER, Kim W and Myung SC: Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol. 106:446–453. 2010. View Article : Google Scholar : PubMed/NCBI
56	Hiss DC, Gabriels GA and Folb PI: Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int. 7:52007. View Article : Google Scholar : PubMed/NCBI
57	Rogan AM, Hamilton TC, Young RC, Klecker RW Jr and Ozols RF: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 224:994–996. 1984. View Article : Google Scholar : PubMed/NCBI
58	Ozols RF: Pharmacologic reversal of drug resistance in ovarian cancer. Semin Oncol. 12(Suppl 4): 7–11. 1985.PubMed/NCBI
59	Gene Ontology consortium. http://www.geneontology.org.
60	Gamberoni G, Storari S and Volinia S: Finding biological process modifications in cancer tissues by mining gene expression correlations. BMC Bioinformatics. 7:62006. View Article : Google Scholar : PubMed/NCBI
61	Lagreid A, Hvidsten TR, Midelfart H, Komorowski J and Sandvik AK: Predicting gene ontology biological process from temporal gene expression patterns. Genome Res. 13:965–979. 2003. View Article : Google Scholar : PubMed/NCBI
62	Medical COREMINE. http://www.coremine.com/medical/.
63	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
64	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
65	Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D and Calin GA: miRNAs and their potential for use against cancer and other diseases. Future Oncol. 3:521–537. 2007. View Article : Google Scholar : PubMed/NCBI
66	Brazil DP, Park J and Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell. 111:293–303. 2002. View Article : Google Scholar : PubMed/NCBI
67	Tang W, Jiang Y, Mu X, Xu L, Cheng W and Wang X: MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal. 26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
68	Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
69	Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
70	Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 69:8910–8917. 2009. View Article : Google Scholar
71	Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA and Brard L: Effect of a vitamin D₃ derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Invest New Drugs. 28:543–553. 2010. View Article : Google Scholar :
72	Jiao JW and Wen F: Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep. 25:781–788. 2011.
73	Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK and Kakar SS: MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines. J Ovarian Res. 4:172011. View Article : Google Scholar
74	Jin L, Huo Y, Zheng Z, Jiang X and Deng H, Chen Y, Lian Q, Ge R and Deng H: Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics. 13:3138–3151. 2014. View Article : Google Scholar : PubMed/NCBI
75	Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M and Tian Y: Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer. Oncol Rep. 32:979–988. 2014.PubMed/NCBI
76	Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar
77	Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S, et al: MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg. 94:1094–1102; discussion 1102–1093. 2012. View Article : Google Scholar : PubMed/NCBI
78	Wang FJ, Ding Y, Mao YY, Jing FY, Zhang ZY, Jiang LF, Guo JF, Sun XJ, Jin MJ and Chen K: Associations between hsa-miR-603 polymorphism, lifestyle-related factors and colorectal cancer risk. Cancer Biomark. 14:225–231. 2014.PubMed/NCBI
79	Rogler A, Hoja S, Socher E, Nolte E, Wach S, Wieland W, Hofstädter F, Goebell PJ, Wullich B, Hartmann A, et al: Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk. Int J Clin Exp Pathol. 6:1984–1998. 2013.PubMed/NCBI
80	Zhang J, Zhang T, Ti X, Shi J, Wu C, Ren X and Yin H: Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun. 399:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
81	Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012. View Article : Google Scholar
82	Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S and Pepe S: A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar
83	Tang J, Tao ZH, Wen D, Wan JL, Liu DL, Zhang S, Cui JF, Sun HC, Wang L, Zhou J, et al: MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling. Biochem Biophys Res Commun. 447:210–215. 2014. View Article : Google Scholar : PubMed/NCBI
84	Yang Y, Li H, Hou S, Hu B, Liu J and Wang J: The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI
85	Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G and Shimizu K: Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One. 7:e314222012. View Article : Google Scholar : PubMed/NCBI
86	Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang F and Zhang SC: miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl). 126:4435–4439. 2013.
87	Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, et al: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 210:951–968. 2013. View Article : Google Scholar : PubMed/NCBI
88	Huang JW, Wang Y, Dhillon KK, Calses P, Villegas E, Mitchell PS, Tewari M, Kemp CJ and Taniguchi T: Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res. 11:1564–1573. 2013. View Article : Google Scholar : PubMed/NCBI
89	Huang N, Shah PK and Li C: Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinform. 13:305–316. 2012. View Article : Google Scholar :
90	McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al; Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar
91	Sharan R, Ulitsky I and Shamir R: Network-based prediction of protein function. Mol Syst Biol. 3:882007. View Article : Google Scholar : PubMed/NCBI
92	Phuong T and Nhung N: Predicting gene function using similarity learning. BMC Genomics. 14(Suppl 4): S42013. View Article : Google Scholar : PubMed/NCBI
93	Janga SC, Díaz-Mejía JJ and Moreno-Hagelsieb G: Network-based function prediction and interactomics: The case for metabolic enzymes. Metab Eng. 13:1–10. 2011. View Article : Google Scholar
94	Yu G, Zhu H, Domeniconi C and Guo M: Integrating multiple networks for protein function prediction. BMC Syst Biol. 9(Suppl 1): S32015. View Article : Google Scholar : PubMed/NCBI
95	Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin F: Downregulation of NEK11 is associated with drug resistance in ovarian cancer. Int J Oncol. 45:1266–1274. 2014.PubMed/NCBI
96	Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin F: Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep. 31:745–754. 2014.
97	Yin F, Liu L, Liu X, Li G, Zheng L, Li D, Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. Oncol Rep. 32:362–372. 2014.PubMed/NCBI
98	Zeng X, Yin F, Liu X, Xu J, Xu Y, Huang J, Nan Y and Qiu X: Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma. Oncol Rep. 31:1139–1146. 2014.PubMed/NCBI
99	Liu J, Wang LY, Yang AJ, Jiang PF and Wang MC: Up-regulation of SALL4 associated with poor prognosis in gastric cancer. Hepatogastroenterology. 61:1459–1464. 2014.PubMed/NCBI
100	Jaber N, Dou Z, Lin RZ, Zhang J and Zong WX: Mammalian PIK3C3/VPS34: The key to autophagic processing in liver and heart. Autophagy. 8:707–708. 2012. View Article : Google Scholar : PubMed/NCBI
101	Yang ZJ, Chee CE, Huang S and Sinicrope FA: The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
102	Peracchio C, Alabiso O, Valente G and Isidoro C: Involvement of autophagy in ovarian cancer: A working hypothesis. J Ovarian Res. 5:222012. View Article : Google Scholar : PubMed/NCBI
103	Wang J and Wu GS: Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
104	Veldhoen RA, Banman SL, Hemmerling DR, Odsen R, Simmen T, Simmonds AJ, Underhill DA and Goping IS: The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene. 32:736–746. 2013. View Article : Google Scholar